Skip to main content
Premium Trial:

Request an Annual Quote

ValiFinn Buys Pharmatest Services' Biomarker Business

NEW YORK (GenomeWeb News) – ValiRx today announced its wholly owned subsidiary ValiFinn has bought the biomarkers business of Pharmatest Services for €75,000 ($96,000) plus stock.

The purchase includes five patent families and patent applications and related intellectual property. Pharmatest, based in Finland, also received 15 million shares of ValiRx stock at a price of .52 pence per share.

Pharmatest also is eligible to receive royalties based on future revenues related to the purchased IP and for the life of the patents, ValiRx said.

ValiFinn plans to create a new business unit with the biomarker business, which currently provides contract research services to pharmaceutical companies. ValiFinn will leverage the business to further the development of companion biomarker diagnostics to complement ValiRx's therapeutics, IP, and companion diagnostic work.

Based in London, ValiRx is focused on developing cancer diagnostics and therapeutics using epigenomics technology. It said in a statement that pairing biomarker-based diagnostics with a targeted drug "is emerging as a key part of personalized medicine, particularly in cancer patients."

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.